Alkermes PLC (NASDAQ:ALKS) Director Paul J. Mitchell sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $51.98, for a total value of $51,980.00. Following the completion of the sale, the director now owns 9,000 shares of the company’s stock, valued at approximately $467,820. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Alkermes PLC (NASDAQ ALKS) traded up $1.41 during trading on Friday, hitting $53.70. The company had a trading volume of 1,692,614 shares, compared to its average volume of 839,906. The company has a quick ratio of 2.72, a current ratio of 3.05 and a debt-to-equity ratio of 0.23. Alkermes PLC has a 1-year low of $46.42 and a 1-year high of $63.40.

Alkermes (NASDAQ:ALKS) last posted its earnings results on Thursday, October 26th. The company reported $0.03 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.01) by $0.04. The business had revenue of $217.40 million during the quarter, compared to the consensus estimate of $231.29 million. Alkermes had a negative return on equity of 7.27% and a negative net margin of 20.12%. Alkermes’s revenue was up 20.6% on a year-over-year basis. During the same quarter last year, the company earned ($0.09) EPS. equities research analysts forecast that Alkermes PLC will post -0.59 EPS for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the stock. Toronto Dominion Bank increased its holdings in Alkermes by 12.7% during the 2nd quarter. Toronto Dominion Bank now owns 1,875 shares of the company’s stock valued at $109,000 after purchasing an additional 212 shares in the last quarter. Quantbot Technologies LP acquired a new stake in Alkermes during the 3rd quarter valued at $126,000. Greenwood Capital Associates LLC increased its holdings in Alkermes by 1.1% during the 2nd quarter. Greenwood Capital Associates LLC now owns 3,770 shares of the company’s stock valued at $219,000 after purchasing an additional 41 shares in the last quarter. Virtu Financial LLC acquired a new stake in Alkermes during the 3rd quarter valued at $201,000. Finally, US Bancorp DE increased its holdings in Alkermes by 366.4% during the 2nd quarter. US Bancorp DE now owns 3,974 shares of the company’s stock valued at $231,000 after purchasing an additional 3,122 shares in the last quarter. 99.75% of the stock is owned by hedge funds and other institutional investors.

A number of analysts have commented on the company. Credit Suisse Group reduced their price objective on Alkermes from $70.00 to $66.00 and set an “outperform” rating for the company in a research report on Friday, October 27th. Barclays set a $50.00 target price on Alkermes and gave the stock a “hold” rating in a research report on Thursday, October 26th. Citigroup set a $62.00 target price on Alkermes and gave the stock a “hold” rating in a research report on Thursday, October 26th. BidaskClub downgraded Alkermes from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 9th. Finally, Mizuho set a $81.00 target price on Alkermes and gave the stock a “buy” rating in a research report on Saturday, October 21st. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $63.55.

TRADEMARK VIOLATION NOTICE: “Alkermes PLC (ALKS) Director Paul J. Mitchell Sells 1,000 Shares” was first reported by Daily Political and is the property of of Daily Political. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/12/01/alkermes-plc-alks-director-paul-j-mitchell-sells-1000-shares.html.

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Insider Buying and Selling by Quarter for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with MarketBeat.com's FREE daily email newsletter.